Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Sodium-driven chloride bicarbonate exchanger (SLC4A10, also known as NBCn2 or NCBE) is a membrane protein primarily expressed in the brain, including principal and inhibitory neurons as well as choroid plexus epithelial cells[2][3][4][8]. It functions as a sodium/bicarbonate cotransporter and plays a key role in regulating intracellular and extracellular pH, neuronal excitability, and cerebrospinal fluid secretion[3][6][8]. SLC4A10 mediates the electroneutral transport of sodium and bicarbonate ions, originally thought to act as a chloride-bicarbonate exchanger, but its physiological chloride exchange is limited under normal conditions[2][3]. Disruption of SLC4A10 is associated with reduced neuronal excitability, decreased risk of seizures, and neurological deficits including epilepsy and cognitive impairment[2][3]. SLC4A10 is considered a potential therapeutic target for epilepsy and disorders involving brain pH homeostasis[2][3].
No approved drugs, but theoretical mechanisms include alteration of neuronal pH homeostasis, modulation of neurotransmitter vesicle pH, and cerebrospinal fluid regulation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Sodium-driven chloride bicarbonate exchanger (SLC4A10).